The clonal relationships between pre-cancer and cancer revealed by ultra-deep sequencing by Wood, HM et al.
This article is protected by copyright. All rights reserved 
The clonal relationships between pre-cancer and cancer revealed 
by ultra-deep sequencing 
 
Henry M Wood1*, Caroline Conway1,4, Catherine Daly1, Rebecca Chalkley1, Stefano Berri1,5, Burcu 
Senguven1,6, Lucy Stead1, Lisa Ross1, Philip Egan1, Preetha Chengot2, Jennifer Graham2, Neeraj 
Sethi1, Thian K Ong3, Alec High2, Kenneth MacLennan1,2, Pamela Rabbitts1. 
 
1 Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, UK 
2 St James's Institute of Oncology, St James’s University Hospital, Leeds, LS9 7TF, UK 
3 Leeds Dental Institute, Leeds General Infirmary, Leeds, LS2 9LU, UK 
4 Now at School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, BT52 1SA, 
UK 
5 Now at Illumina UK Ltd., Chesterford Research Park, Saffron Walden, CB10 1XL, UK. 
6 Now at Department of Oral Pathology, Faculty of Dentistry, Gazi University, Turkey. 
 
 
* Correspondence to:   
Email: h.m.wood@leeds.ac.uk, +44 (0)113 2064070 
 
 
Disclosure Declaration 
None of the authors of this work has any conflict of interest. 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/path.4576 
  
This article is protected by copyright. All rights reserved 
 
Abstract 
The study of the relationships between pre-cancer and cancer and identification of early driver 
mutations is becoming increasingly important as the value of molecular markers of early disease and 
personalised drug targets is recognised, especially now the extent of clonal heterogeneity in fully 
invasive disease is being realised. It has been assumed that pre-cancerous lesions exhibit a fairly 
passive progression to invasive disease; the degree to which they too are heterogeneous is unknown. 
We performed ultra-deep sequencing of thousands of selected mutations together with copy number 
analysis from multiple, matched pre-invasive lesions, primary tumours and metastases from five 
patients with oral cancer, some with multiple primary tumours presenting either synchronously or 
metachronously, totalling 75 samples. This allowed the clonal relationships between the samples to 
be observed for each patient. 
We expose for the first time the unexpected variety and complexity of the relationships between this 
group of oral dysplasias and their associated carcinomas, and ultimately, the diversity of processes by 
which tumours are initiated, spread and metastasise.  
Instead of a series of genomic precursors of their adjacent invasive disease, we have shown 
dysplasia to be a distinct dynamic entity, refuting the belief that pre-cancer and invasive tumours with 
a close spatial relationship always have linearly-related genomes. We show that oral pre-cancer 
exhibits considerable sub-clonal heterogeneity in its own right, that mutational changes in pre-cancer 
do not predict the onset of invasion, and that the genomic pathway to invasion is neither unified nor 
predictable. 
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Introduction 
Genomic changes occurring consistently in tumours provide the opportunity to develop disease 
markers for diagnosis, prognosis and prediction of treatment response, and targets for drug treatment. 
The international efforts to catalogue genomic changes in tumours [1] are testament to the near 
universal acceptance of this prospect. Identifying which changes occur early in development has 
always been recognised as of value, increasingly so now that the genomic heterogeneity of fully 
invasive tumours is being revealed [2-5]. 
Carcinomas (especially those with squamous cell histology) often have a recognised pre-cancerous 
stage, epithelial dysplasia. This provides an opportunity for direct identification of the earliest genomic 
changes, although the genomes of pre-cancerous lesions receive little attention, most probably due to 
their small size and the difficulty of obtaining tissue. However, oral cancer is an excellent source of 
pre-cancerous lesions because its associated dysplasia can be manifest in macroscopically visible 
lesions including erythroplakia and leukoplakia and is almost always present adjacent to fully-
malignant carcinoma within the field of tumour resection.  This has enabled several studies to 
compare the genomes of unrelated pre-invasive lesions and carcinomas [6,7], as well as a few 
comparing lesions from the same patients [8-10]. Copy number aberrations (CNAs) and microsatellite 
loci have been linked with early disease and progression.. 
An additional feature of oral cancer is that the disease is often multifocal. Clinical presentation of 
lesions  can be both synchronously and metachronously and lesions are frequently clonally related 
[11]. In the present  study we took advantage of this to examine five patients with between 11 and 22 
samples each. Rather than examine candidate genes, we used high-throughput sequencing to 
produce an unbiased catalogue of genomic changes for each patient, enabling those changes 
occurring at a pre-invasive stage, representing the earliest events, to be clearly identified. 
An immediate outcome of our analysis was that the distribution of mutations between the various 
lesions was unpredictable, indicating that many sub-clones co-existed even at the earliest stages of 
disease. By identifying classes of co-occurring mutations within each patient’s group of lesions, we 
were able to chart the chronology of genomic changes and from this the natural history of each 
patient’s disease. 
 
Materials and methods 
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Samples 
Patients were recruited from the Oral and Maxillofacial Surgery Outpatients' clinic of Leeds General 
Infirmary and informed consent obtained (ethics REC ref no 07/Q1206/30 and 08/H1306/127). Fresh 
frozen samples and blood were collected in clinic or from the operating theatre. Formalin-fixed, 
paraffin-embedded (FFPE) blocks were retrieved from the hospital archives. Following sectioning and 
dissection where appropriate, DNA was prepared using commercial kits (Qiagen, City, State/Province, 
Country). 
 
Selection of mutations for analysis 
Mutations were selected for each patient based on whole genome (fresh samples) and exome (FFPE 
samples) sequencing from between three and five samples per patient. Where more than 8µg DNA 
was available, sequencing was carried out by Complete Genomics and analysed using their 
proprietary pipeline [12]. For samples with less than 8µg DNA, whole genomes were sequenced using 
an Illumina HiSeq 2000, to 30X coverage. Reads were aligned to the human genome (hg19) using 
BWA 0.5.9 [13], processed using the GATK pipeline 1.3.8 [14], and mutations called using SNVmix2 
0.11.8 [15,16]. Exome capture of FFPE samples and matching blood was performed using the 
Sureselect Human All Exome kit (Agilent). An average of 50X coverage was obtained using an 
Illumina HiSeq2500. Reads were aligned to the human genome, processed using GATK, and 
mutations called using Varscan2 2.3.5 [17] in somatic mode under default parameters. Due to the mix 
of sequencing platforms used, these results were only used to nominate mutations for further 
analysis, and were not used to compare samples directly.  
Haloplex custom capture kits (Agilent) were designed to capture the nominated mutations for 
validation and direct comparison between patients. 10,000 putative somatic variants per patient were 
chosen for validation and clonal analysis. The selection was enriched for genes and spanned a range 
of mutant allele frequencies. Additionally, the potential effects of mutations were assessed using the 
Variant Effect Predictor [18] and Chasm 3.0 [19]. PCR primers for the 30 variants per patient deemed 
to have the most likely carcinogenic properties were designed using Primer3 2.2.3 [20] to increase the 
chances that the most informative mutations would be sequenced at high depth.  
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Deep sequencing of selected variants: 
Libraries were prepared from the Haloplex kits for all samples and sequenced on an Illumina HiSeq 
2500 to an average of 600X coverage. The PCR-captured variants were sequenced on an Illumina 
MiSeq to at least 3000X coverage. All reads were aligned to the human genome, processed using 
GATK, and mutations called using Varscan2 in somatic mode under default parameters.  
Only variants that were completely absent in the normal blood sample, had a depth of at least 50X in 
all samples and which were on the original list used for Haloplex/PCR design were considered for 
clonal analysis. These mutations had, therefore, all been called by one sequencing method and then 
validated by another method in at least two samples. This ensured that no results were based on de 
novo mutation calls, minimising the chance of results being biased by any FFPE damage, or other 
sequencing or mutation-calling artefact. 
 
Low coverage copy number sequencing and viral detection 
Copy number data was obtained from all samples using previously published protocols [21]. DNA was 
sequenced on an Illumina HiSeq 2500 to around 0.15X coverage, and aligned to the human genome 
using BWA. Copy number data was produced using CNAnorm 1.3.5 [22] under default parameters 
with manual correction to allow for heterogeneous regions of copy number change, using a control 
sample generated by pooling reads from 20 British Caucasian individuals from the 1000 Genomes 
Project [23]. Breakpoints were called using DNAcopy 1.36.0 [24]. 
The same sequence data was also aligned to all known viral sequences to detect any Human 
Papillomavirus (HPV) infection [25]. 
 
Clonal reconstruction (see also supplementary information online) 
Mutations were assigned to classes, and clonal relationships assigned, using methods similar to those 
in Newburger et al. [26], based on patterns of co-occurrence. The presence or absence of each 
mutation or copy number breakpoint across all samples was noted and combined to form a text string, 
e,g. 11011 or 01101 for two mutations across five samples. The strings for all events were compared, 
and identical strings grouped together to form classes. These classes represented detectable sub-
clones. Classes supported by only one point mutation were discarded because of the increased 
chance of error due to miscalling, unless that point mutation was captured both by haloplex and PCR. 
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The cellular frequencies of copy number events were estimated for each sample using CNAnorm. 
Cellular frequencies of point mutations were estimated using PyClone 0.12.7 [27] taking into account 
epithelial cell content, overall ploidy and local copy number. Co-occurring classes were examined to 
ascertain if any two classes were present in over 50% of cells in a sample. This would indicate, by the 
pigeonholing principle, that there must be some cells containing both classes, therefore, the classes 
must be part of the same sequential lineage.  
Each sample had a large number (14-89) of private mutations, only found in that sample and mostly at 
low frequencies. These were not considered for clonal analysis and had a higher chance of being 
spurious because they were not validated in more than one sample. 
 
Results 
 
Sequencing summary (see also supplementary information online) 
We examined the clonal relationships between samples for five patients. Detailed clinical and sample 
information for each patient is given in the supplement, along with sequencing metrics for each 
sample. C.G > T.A mismatch rates, a known proxy for FFPE damage [28], were measured and found 
to vary very little between fresh and fixed samples. Between 837 and 2039 putative somatic mutations 
were validated out of 10000 in at least one sample per patient. Between 544 and 1258 of these were 
re-sequenced in enough depth (>50X) in all samples to be considered for clonal analysis, together 
with copy number data. Between 17 and 32 classes of somatic events were segregated according to 
patterns of co-occurrence (Table 1). Lists of point mutations, CNAs and classes for the five patients 
denoted as PG008, PG055, PG030, PG136 and PG019 are shown respectively in Supplementary 
Tables S6 and S7; S8 and S9; S10 and S11; S12 and S13; and S14.  
 
Patients’ summary  
Each patient is described in brief below and in more detail in supplementary information online..  
Patient PG008 (Figure 1) had a left ventral tongue lesion. The HGD sample shared only one CNA with 
the rest of the lesion. A small proportion of the cells in the LGD sample contained 17 mutations (class 
2, including a TP53 mutation) that were ubiquitous throughout the carcinoma samples. From this 
single clonal origin, the carcinoma exhibited spatial heterogeneity. 
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Patient PG055 (Figure 2) had an HPV-driven lesion in the floor of mouth. The normal samples 
exhibited no viral infection. One marginal dysplasia sample shared only two CNAs with the rest of the 
lesion. The remaining samples shared 172 mutations (class 2). This common ancestor split into two 
sub-clones. Class 3 was only found in dysplasia samples. Class 4 was found in all carcinoma samples 
and as a sub-clonal fraction in the part of the dysplasia nearest the carcinoma. All of the carcinoma 
samples contained the class 6 events not found in any dysplasia samples. Most of the dysplasia 
samples were therefore dominated by sub-clones not found in the carcinoma.  
Patient PG030 (Figure 3) presented with a right retromolar lesion, a left floor of mouth lesion and 
right-sided neck metastases. The disease appears to have originated in the right lesion. TP53 was 
amongst the earliest genes mutated (class 2), in all neoplastic samples apart from one dysplasia. The 
biggest split in samples was between classes 3 and 4. Class 3 was absent in the left lesion. Class 4 
was absent in the dysplasia furthest from the left lesion, but ubiquitous on the left. Both were present 
throughout the right-sided carcinoma and metastases, indicating mixed populations. The fact that this 
mixing was replicated in the metastases indicates that the metastatic event involved a population of 
cells, rather than just one founder. As every right-sided invasive sample contained both sub-clones, it 
is possible that they depended on each other in some way, cooperating to maintain the invasive 
phenotype. It is unclear if class 7, only found in invasive samples, arose in cells with class 3, 4 or 5 
mutations, or represented a mixture of sub-clones descended from a combination of them. It was 
never found with only one of its potential ancestors (which were themselves not always found 
together), suggesting that one sub-clone alone was not enough to maintain invasion. Every left-sided 
sample contained class 6, which was only found in one dysplasia sample on the right side. 
Patient PG136 (Figure 4) had a right lateral tongue lesion with nodal metastases. Unusually, this 
patient had no history of alcohol or tobacco use, or evidence of viral infection. Very few point 
mutations were present at high cellular frequencies, and none were shared between samples. Only 
copy number data is presented here. Some common events were found in adjacent normal tissue, 
while not appearing in all dysplasia samples, suggesting that the histological definition of normal did 
not always match the genomic profile. Most samples contained events at both clonal and sub-clonal 
cellular frequencies, indicating considerable heterogeneity, with clonal events in some samples 
appearing to be sub-clonal in others. There did however appear to be a dominant population at high 
cellular frequencies in all the SCC samples, appearing at class 5. The only homogenous samples 
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were the biopsy, whose small size may have reduced the diversity sampled, and the metastases, 
indicating that only some of the multiple sub-clones detected had been able to successfully 
metastasise.  
Patient PG019 (Figure 5) presented with multiple lesions over a 19-year period. All samples, including 
the earliest normal tissue, contained the 35 class 1 mutations, including a TP53 mutation. We 
detected a cumulative increase in mutations from 1992 to 2007, when an additional TP53 mutation 
(class 4) coincided with an increase in the frequency of lesions arising. A clone (class 5) first detected 
in 2008 was seen in the 2009 carcinoma samples, but not the 2009 adjacent dysplasia and normal 
samples, suggesting that the 2009 lesion had a mixed clonal ancestry. This could have occurred 
through multiple colonisations of the region, or through colonisation by a mixed population of cells. In 
the 2009 dysplasia and normal samples, and all subsequent samples, we only detected the pre-2008 
classes. Mutations first detected in the 1992 and 2009 carcinomas (classes 2 and 6), were never 
detected subsequently, indicating successful surgical removal. 
 
 
Heterogeneity of carcinomas 
Clonal variation between and within carcinoma samples from the same lesion was detected in all five 
patients. The two patients with multiple lesions also demonstrated variation between lesions. Patients 
PG008, PG055 and PG136 showed the simplest pattern, whereby a single founder sub-clone for all 
carcinoma samples was detected. This then diverged into a more heterogeneous population in an 
approximately spatial pattern. Patient PG019 showed differences between pre-2007 lesions and post-
2007 lesions. There was some evidence that the 2009 lesion was founded by a mixed population of 
sub-clones. Patient PG030 was the most complex. Every carcinoma in the right lesion appeared to 
contain the same mixed population of sub-clones, with no detectable spatial variation. The left lesion 
contained a different mixture of sub-clones, related to a subset of those from the right, with additional 
spatial variation detected. 
 
Heterogeneity of dysplasias 
Patient PG019 displayed variation between different lesions, but none was detectable within any one 
individual lesion. For the remaining four patients, sub-clonal variation was detected between 
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dysplastic samples from the same lesion. The variation was not a case of simple progression towards 
carcinoma, with different samples capturing different stages along that progression. A number of 
dysplasia-only sub-clones were also detected, most notably in patients PG055 (class 3) and PG136 
(classes 3 and 4). 
 
Progression from normal to dysplasia 
Patients PG008 and PG055 showed clear distinction between normal and neoplastic samples. PG030 
and PG136 showed overlap in the genomic profiles of some normal and some dysplasia samples, 
hinting that histologically normal cells may have harboured dysplastic mutations. PG019 normal 
samples all contained the major sub-clone detected in their adjacent dysplasia. Only two low-grade 
dysplasia samples were collected, and they both contained mutations that were absent from nearby 
high-grade dysplasia samples but were however found in carcinoma, suggesting that histological 
grade and genomic profiles did not closely correlate. 
 
Progression from dysplasia to carcinoma 
The carcinoma samples from PG008 and PG055 both showed a clear monoclonal origin, which was 
detectable in a small population of cells in one dysplasia sample, and was itself descended from the 
common ancestor of all the dysplasia samples. PG136 was too heterogeneous to confidently predict 
the origin of the invasive clone. Most PG019 carcinomas were indistinguishable from their associated 
dysplasia. The exception was the 2009 lesion. The carcinoma appeared to be closely related to the 
2008 dysplasia, while the 2009 dysplasia was more closely related to the 2007 disease. The 2009 
carcinoma was therefore not descended from its adjacent dysplasia. The right lesion of PG030 
appeared to contain two distinct populations. Descendants of both of these were found in every 
carcinoma sample, indicating some kind of clonal cooperation. The left lesion was descended from 
just one of the right-sided dysplastic sub-clones, not from a right-sided carcinoma sample. Once this 
sub-clone had arrived on the left, the subsequent dysplasia and carcinoma samples were 
indistinguishable. 
 
Metastasis 
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Two patients presented with metastases. The PG030 primary carcinoma exhibited a mixed population 
of at least two distinct sub-clones. This heterogeneity was maintained in the metastases, suggesting a 
population of cells metastasising. The PG136 primary lesion was even more heterogeneous, but the 
metastases showed a clear monoclonal origin.  This could imply selection of a metastatic clone, or it is 
also possible that the heterogeneity in PG030 was a result of clonal cooperation, and was thus 
necessary to found a metastasis, whereas the PG136 heterogeneity was possibly merely a product of 
constant accumulation of passenger events and was not necessary to maintain. 
 
Discussion 
 
This study has revealed in unprecedented detail the clonal relationships between pre-cancer and 
cancer from the same patients, charting the chronological order of genomic changes as lesions 
developed. 
It has been generally believed that the relationship between dysplasia and carcinoma is a relatively 
simple one, and that in comparison with the carcinoma, the dysplasia is fairly passive, with mutations 
gradually accumulating until some of the cells become invasive. Our results expose the scale of 
variety and the complexity of relationships between dysplasia and invasive oral carcinoma. One 
patient (PG008) displayed classical progression, with gradual accumulation of mutations leading to 
invasion, whereas other patients showed considerable sub-clonal heterogeneity within the dysplasia 
itself, with dysplastic sub-clones independently acquiring mutations in several oncogenes without 
becoming invasive. PG019 and PG030 showed evidence of dysplastic cells leaving the primary 
tumour and seeding fresh lesions and of mutationally-similar cells having invasive or non-invasive 
phenotype depending on their surroundings. PG030 also showed potential cooperation between sub-
clones to maintain a lesion. 
 
Study design 
When studying the relationship between dysplasias and carcinoma, the usual method is to examine 
groups of both types of sample [6,7]. The number of studies of dysplasia and carcinoma in the same 
patient are very few. They tend to examine candidates such as TP53 or microsatellites and use 
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limited sample numbers, so the full extent to which different morphological grades, or different regions 
of the same lesion are similar or different is not fully exposed [8,9]. 
By combining point mutation and CNA data, and using multiple samples per patient, we have been 
able not only to show the relationships between different cell populations within and between lesions, 
but also to associate tumour progression in each patient with specific genomic changes and infer the 
processes by which each lesion was initiated, developed and then spread. 
We chose to use the recently described method [3-5] whereby initial sequencing results are used to 
nominate a selected group of mutations for much deeper sequencing. Our clonal relationships were 
entirely derived from the capture and CNA results, with no further input from our initial sequencing 
experiments. There have been a number of informatics approaches published [27,29,30] to infer sub-
clonal architecture in tumour samples. These cluster mutations using accurately measured cellular 
frequencies. However, in common with another recent study [26], we found that our mutations did 
always split into multiple distinct clusters. As for that project and one other [2], we had the advantage 
of working with large numbers of samples per patient. Therefore we were able to adopt a similar 
approach and classify mutations by patterns of co-occurrence, relying on direct observations of 
mutation presence or absence, rather than inferring relationships from cellular frequencies which are 
themselves inferred. 
 
TP53 
We have listed all the mutations validated in our samples (Supplementary Tables S6, S8, S10, S12, 
S14). Some genes were mutated in more than one patient, but not in an early clone shared between 
many samples. The only gene that was frequently mutated at an early stage of development was 
TP53. 
It has long been suspected that the TP53 gene is important in head and neck SCC, and that it is often 
mutated in dysplasia as well as carcinoma [31-33]. This was confirmed by a recent exome sequencing 
study, which showed that TP53 was by far the most commonly mutated gene and that P53 
inactivation, either by mutation or HPV infection, was almost universal for this disease [34].  Our 
results reiterate that finding, and confirm that where present (by mutation in three patients and with 
HPV infection in one), it was always amongst the earliest changes detected. In PG019, a second 
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subsequent TP53 mutation coincided with more aggressive disease, making it likely that in 
conbination the two mutations totally ablated P53 protein. 
 
The natural history of head and neck SCC 
The frequent observation of the close physical association of dysplasia and carcinoma in head and 
neck SCC is generally believed to be indicative of a sequential developmental relationship [35-38].  
In this study, the dysplasia samples all shared a common ancestor with the nearby SCC, but were not 
necessarily directly ancestral to it. The SCC samples were usually descended from a minor sub-clone 
from within one of the dysplasia samples. In the case of PG030 and PG019, SCC samples were 
descended from a relatively distant dysplasia sample, rather than the adjacent one. 
All patients exhibited some level of dysplastic heterogeneity, which was particularly pronounced in 
patients PG055 and PG136. These samples showed evidence that the dysplasias developed 
considerable clonal variation before the invasive clone emerged, and have possibly continued to 
evolve since [39]. 
Many different pathways capable of generating HNSCC have been proposed, and associated with 
tobacco, alcohol use and viral infection [34,40-42]. Our five patients all developed their histologically 
similar tumours in different ways. PG136 appeared almost devoid of point mutations, so it is not 
known how the disease was triggered. PG055 was fuelled by viral infection. PG008 either had a very 
inactive, or short pre-cancerous phase, with most mutations occurring from either shortly before 
invasion, or afterwards. 
Both lesions from PG030 were mixed populations, with all samples containing multiple sub-clones, 
leading to the possibility that they depended on each other to maintain an invasive phenotype, as has 
recently been described in breast cancer [43]. The left lesion was seeded by a pre-cancerous sub-
clone from the right lesion. PG019 showed a slow disease progression, with gradual increase in 
aggressiveness as mutations accumulated, and eventual spread of mutated cells throughout the oral 
cavity. 
 
Patterns of tumour evolution 
Six possible different patterns of tumour initiation and progression have been inferred from our 
observations. These processes are summarised in Figure 6. Most patients exhibited more than one of 
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these processes as their disease spread to a different part of the oral cavity or metastasised. These 
only represent the patterns inferred from these five patients, rather than any general rule. The fact that 
six patterns were inferred from only five patients suggests that applying any general rules to HNSCC 
development is a very simplistic approach. 
The simplest process is characterised by local initiation and progression (Figure 6A). Initial mutations 
in normal tissue give rise to dysplasia containing one or more sub-clones. In one of these sub-clones, 
further mutations give rise to an invasive clone. This was observed in PG008, PG055 and PG136. 
Slightly more complex is the possibility of cooperating sub-clones (Figure 6B). PG030 invasive 
samples all contained multiple sub-clones that were also seen in non-invasive samples, sometimes in 
a majority of cells. It is possible that the sub-clones depend on each other to maintain an invasive 
phenotype. New SCCs were also seeded by distant dysplasias (Figure 6C) either spreading through 
the epithelium [11] or by detaching and alighting in the new position [44]. Most of the PG019 SCCs 
and the left lesion from PG030 developed this way. The PG019 2009 SCC was founded by new cells 
(from the 2008 lesion) seeding an area that has already been colonised by the 2007 clone (Figure 
6D). 
Two types of nodal metastasis were seen. In PG030, the sub-clonal variation of the primary tumour 
was maintained in the metastases (Figure 6E), whereas in PG136, a heterogeneous primary tumour 
gave rise to a single metastatic clone (Figure 6F). 
 
Conclusions 
 
The work described here exposes the diversity of processes by which histologically similar tumours 
are initiated, develop and spread, and the hitherto unknown complexity in the relationships between 
pre-invasive and invasive disease. We show that dysplasia has considerable sub-clonal variation, and 
that a carcinoma is often descended from a minority sub-clone in just part of that dysplasia. 
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Table 1: Patient summary: Brief clinical details are shown for each patient, the numbers of somatic 
mutations validated, and the number of mutations sequenced to at least 50X coverage in all samples 
used to generate classes, as well as the number of derived classes. 
 
Patient Main clinical 
features 
Risk 
Factors 
TMN 
status 
Samples Somatic 
mutations 
Shared 
somatic 
mutations 
Validated 
somatic 
mutations 
Mutations 
used in 
analysis 
Classes
PG008 Single tumour Alcohol, 
tobacco 
pT2N0M0 10 FR-D  
166185 
3656 837 543 17
FR-C  17433
PG019 Multiple 
tumours over 
20 year period. 
Previous 
smoker 
pT1N0M0 
(first 
tumour) 
18 FR-1-D 
134164 
57477 2039 795 22
FR-2-D 
186770 
FR-C  23140
PG030 Two 
synchronous 
tumours. Neck 
metastases. 
Alcohol, 
tobacco 
pT2N2bM0 
(right) 
pT2N0M0 
(left) 
22 L-FR-C 
213601 
1161 1454 921 32
R-FR-C 
12791 
PG055 Single tumour HPV pT1N0M0 11 FR-D 106499 34263 1593 1038 19
FR-C 102403
PG136 Single tumour. 
Neck 
metastases. 
None pT2N2bM0 14 FR-1-D 
910626 
1598 905 683 24
FR-1-C 
14841 
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